copyright © 2011 research to practice. all rights reserved. faculty national gi tumor board...
Post on 04-Jan-2016
215 Views
Preview:
TRANSCRIPT
Copyright © 2011 Research To Practice. All rights reserved.
Faculty
National GI Tumor Board
Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer
Friday, January 21, 20117:00 PM – 9:30 PM
San Francisco, California
ModeratorNeil Love, MD
Eileen M O’Reilly, MDEric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD
Charles D Blanke, MDDavid Cunningham, MDSteven A Curley, MD
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
Copyright © 2011 Research To Practice. All rights reserved.
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
Copyright © 2011 Research To Practice. All rights reserved.
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
Copyright © 2011 Research To Practice. All rights reserved.
First Interim Results of the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma (HCC) and of its Treatment with Sorafenib (GIDEON) Study: Use of Sorafenib by Oncologists and Nononcologists in the Management of HCC
Venook AP et al. Proc ASCO GI 2011;Abstract 157
Copyright © 2011 Research To Practice. All rights reserved.
GIDEON Study: First Interim Analysis
Venook AP et al. Proc ASCO GI 2011;Abstract 157.
42%
76%
28%
35%
0% 20% 40% 60% 80% 100%
TreatmentEmergent
Serious AEs
Sorafenib 800 mgInitial Dose
CP-B
Stage 4
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
Copyright © 2011 Research To Practice. All rights reserved.
Faculty
National GI Tumor Board
Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer
Friday, January 21, 20117:00 PM – 9:30 PM
San Francisco, California
ModeratorNeil Love, MD
Eileen M O’Reilly, MDEric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD
Charles D Blanke, MDDavid Cunningham, MDSteven A Curley, MD
Copyright © 2011 Research To Practice. All rights reserved.
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
Abou-Alfa GK et al.JAMA 2010;304(19):62154-60
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
top related